Format
Sort by
Items per page

Send to

Choose Destination

Best matches for cannabidiol and depression:

Cannabidiol in medical marijuana: Research vistas and potential opportunities. Rong C et al. Pharmacol Res. (2017)

Cannabidiol, neuroprotection and neuropsychiatric disorders. Campos AC et al. Pharmacol Res. (2016)

Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of Cannabis sativa. de Mello Schier AR et al. CNS Neurol Disord Drug Targets. (2014)

Search results

Items: 1 to 20 of 106

1.

Is cannabidiol the ideal drug to treat non-motor Parkinson's disease symptoms?

Crippa JAS, Hallak JEC, Zuardi AW, Guimarães FS, Tumas V, Dos Santos RG.

Eur Arch Psychiatry Clin Neurosci. 2019 Jan 31. doi: 10.1007/s00406-019-00982-6. [Epub ahead of print] Review.

PMID:
30706171
2.

Cannabis and Mood Disorders.

Lucatch AM, Coles AS, Hill KP, George TP.

Curr Addict Rep. 2018 Sep;5(3):336-345. doi: 10.1007/s40429-018-0214-y. Epub 2018 May 10.

PMID:
30643708
3.

Effects of cannabidiol in males and females in two different rat models of depression.

Shbiro L, Hen-Shoval D, Hazut N, Rapps K, Dar S, Zalsman G, Mechoulam R, Weller A, Shoval G.

Physiol Behav. 2019 Mar 15;201:59-63. doi: 10.1016/j.physbeh.2018.12.019. Epub 2018 Dec 17.

PMID:
30571957
4.

Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age.

Crippa JA, Guimarães FS, Campos AC, Zuardi AW.

Front Immunol. 2018 Sep 21;9:2009. doi: 10.3389/fimmu.2018.02009. eCollection 2018. Review.

5.

New Perspectives on the Use of Cannabis in the Treatment of Psychiatric Disorders.

Scherma M, Masia P, Deidda M, Fratta W, Tanda G, Fadda P.

Medicines (Basel). 2018 Oct 2;5(4). pii: E107. doi: 10.3390/medicines5040107. Review.

6.

Cannabinoid-Based Therapies and Brain Development: Potential Harmful Effect of Early Modulation of the Endocannabinoid System.

Schonhofen P, Bristot IJ, Crippa JA, Hallak JEC, Zuardi AW, Parsons RB, Klamt F.

CNS Drugs. 2018 Aug;32(8):697-712. doi: 10.1007/s40263-018-0550-4.

PMID:
30109642
7.

A Cross-Sectional Study of Cannabidiol Users.

Corroon J, Phillips JA.

Cannabis Cannabinoid Res. 2018 Jul 1;3(1):152-161. doi: 10.1089/can.2018.0006. eCollection 2018.

8.

Evidence for the use of "medical marijuana" in psychiatric and neurologic disorders.

Noel C.

Ment Health Clin. 2018 Mar 23;7(1):29-38. doi: 10.9740/mhc.2017.01.029. eCollection 2017 Jan.

9.

Antidepressant-like effect induced by Cannabidiol is dependent on brain serotonin levels.

Sales AJ, Crestani CC, Guimarães FS, Joca SRL.

Prog Neuropsychopharmacol Biol Psychiatry. 2018 Aug 30;86:255-261. doi: 10.1016/j.pnpbp.2018.06.002. Epub 2018 Jun 6.

PMID:
29885468
10.

Sub-chronic treatment with cannabidiol but not with URB597 induced a mild antidepressant-like effect in diabetic rats.

de Morais H, Chaves YC, Waltrick APF, Jesus CHA, Genaro K, Crippa JA, da Cunha JM, Zanoveli JM.

Neurosci Lett. 2018 Aug 24;682:62-68. doi: 10.1016/j.neulet.2018.06.006. Epub 2018 Jun 6.

PMID:
29885450
11.

Cannabidiol Induces Rapid and Sustained Antidepressant-Like Effects Through Increased BDNF Signaling and Synaptogenesis in the Prefrontal Cortex.

Sales AJ, Fogaça MV, Sartim AG, Pereira VS, Wegener G, Guimarães FS, Joca SRL.

Mol Neurobiol. 2018 Jun 4. doi: 10.1007/s12035-018-1143-4. [Epub ahead of print]

PMID:
29869197
12.

A Model of Δ9-Tetrahydrocannabinol Self-administration and Reinstatement That Alters Synaptic Plasticity in Nucleus Accumbens.

Spencer S, Neuhofer D, Chioma VC, Garcia-Keller C, Schwartz DJ, Allen N, Scofield MD, Ortiz-Ithier T, Kalivas PW.

Biol Psychiatry. 2018 Oct 15;84(8):601-610. doi: 10.1016/j.biopsych.2018.04.016. Epub 2018 May 3.

PMID:
29861097
13.

[Current and future pharmacotherapy of severe psychiatric disorders].

Češková E.

Cas Lek Cesk. 2018 Spring;157(2):96-100. Czech.

PMID:
29790360
14.

Review of the neurological benefits of phytocannabinoids.

Maroon J, Bost J.

Surg Neurol Int. 2018 Apr 26;9:91. doi: 10.4103/sni.sni_45_18. eCollection 2018. Review.

15.

Prolonged Cannabidiol Treatment Effects on Hippocampal Subfield Volumes in Current Cannabis Users.

Beale C, Broyd SJ, Chye Y, Suo C, Schira M, Galettis P, Martin JH, Yücel M, Solowij N.

Cannabis Cannabinoid Res. 2018 Apr 1;3(1):94-107. doi: 10.1089/can.2017.0047. eCollection 2018.

16.

A naturalistic examination of the perceived effects of cannabis on negative affect.

Cuttler C, Spradlin A, McLaughlin RJ.

J Affect Disord. 2018 Aug 1;235:198-205. doi: 10.1016/j.jad.2018.04.054. Epub 2018 Apr 6.

17.

Novel treatment options in depression and psychosis.

Ceskova E, Silhan P.

Neuropsychiatr Dis Treat. 2018 Mar 13;14:741-747. doi: 10.2147/NDT.S157475. eCollection 2018. Review.

18.

Prospects of Cannabidiol for Easing Status Epilepticus-Induced Epileptogenesis and Related Comorbidities.

Upadhya D, Castro OW, Upadhya R, Shetty AK.

Mol Neurobiol. 2018 Aug;55(8):6956-6964. doi: 10.1007/s12035-018-0898-y. Epub 2018 Jan 25. Review.

PMID:
29372545
19.

Do psychoactive drugs have a therapeutic role in compulsivity? Studies on schedule-induced polydipsia.

Martín-González E, Prados-Pardo Á, Mora S, Flores P, Moreno M.

Psychopharmacology (Berl). 2018 Feb;235(2):419-432. doi: 10.1007/s00213-017-4819-y. Epub 2018 Jan 8.

PMID:
29313138
20.

[The treatment of cannabis dependence: Clinical work, psychotherapy and evidence].

Capece J, Pavlovsky F.

Vertex. 2016 Nov;XXVII(130):469-473. Spanish.

PMID:
28898308

Supplemental Content

Loading ...
Support Center